Why People Stop GLP-1 Medicines: Cost, Side Effects and Real-World Barriers

GLP-1 medicines help many people, but staying on them isn't always simple. Side effects, cost, insurance changes, supply problems, missed appointments and patchy access to clinical support can all affect whether someone keeps going. When a person stops, it's tempting to call it a lack of commitment. Research points to a more useful view: whether people stay on treatment depends on both how the medicine affects them and the conditions of real life.

What real-world research reports

A two-year study from a large nonprofit health system in the US Midwest followed 853 people prescribed a GLP-1 for class 2–3 obesity between 2020 and 2022. About a quarter (24.7%) never received the medicine, and over a third (35.6%) stopped within two years. Among those who stopped, the most common reasons were losing touch with the original prescriber (27%), side effects (24%) and insurance coverage ending (21%). This is one health system's experience, so it doesn't set exact rates for other countries or populations, but it shows why access and continuity of care belong in the conversation.

Patients describe similar barriers in their own words. In a 2026 JAMA Network Open interview study of 30 US adults (most with type 2 diabetes), reasons people gave for stopping included intolerable side effects, cost and other health changes, and many described the effort it took to get coverage. You can read more in what GLP-1 user interviews reveal.

Side effects aren't the only barrier

Ongoing medicine can be expensive, and coverage rules change. A move, a clinic closing, a shortage or a delayed prescription can interrupt care even when someone wants to continue. (There's more on how cost and access shape the GLP-1 journey.) People also weigh benefits against nausea, vomiting, other symptoms or worries about long-term treatment. Each reason calls for a different response.

What to discuss before stopping

If cost or side effects are making treatment hard, tell your prescriber before stopping when you can. Ask about approved alternatives where you live, coverage or savings support, managing symptoms, realistic goals and what to expect if treatment ends. Don't ration doses, stretch the time between doses or switch to unapproved products without guidance. If there's already been a gap, ask for product-specific instructions before restarting, because some labels call for restarting at a lower dose after missed doses.

Why follow-up matters

After stopping, weight and some heart-and-metabolic measures tend to drift back toward where they were, though by how much varies. A 2026 BMJ systematic review of 37 studies (9,341 participants) found average regain of about 0.4 kg per month after weight-management medicines were stopped, with cardiometabolic markers projected to return to baseline within about 1.4 years. Those are averages across many drugs and studies, so they won't predict any one person's path. They support planning ahead, not shame. For the semaglutide-specific evidence, see what happens when you stop semaglutide.

A good system makes it easier to raise barriers before they turn into silent gaps in care. Affordability and tolerability are health issues, not character tests.